Oxytocin is a peptide neurophysin hormone made up of nine amino acids and is used in induction of one in four births worldwide (more than 13 percent in the United States). Herein, we have developed an antibody alternative aptamer-based electrochemical assay for real-time and point-of-care detection of oxytocin in non-invasive saliva samples. This assay approach is rapid, highly sensitive, specific, and cost-effective. Our aptamer-based electrochemical assay can detect as little as 1 pg/mL of oxytocin in less than 2 min in commercially available pooled saliva samples. Additionally, we did not observe any false positive or false negative signals. This electrochemical assay has the potential to be utilized as a point-of-care monitor for rapid and real-time oxytocin detection in various biological samples such as saliva, blood, and hair extracts.
Infections caused by multi-drug-resistant organisms (MDROs) pose a significant public health threat, responsible for over 2 million hospitalizations and 23,000 deaths annually in the United States. Microbiome dysbiosis (imbalance) is considered one of the main causes for MDRO colonization and the resulting infections. Rapid detection and intervention of MDRO outbreaks are crucial to alleviating strain on patients and healthcare facilities. Current diagnostic methods for MDRO detection are too slow and costly to provide the rapid MDRO detection necessary for patient care facilities. Here we present a rapid, accurate and cost-effective electrochemical sensor capable of MDRO detection down to ∼10 4 colony forming units (CFU)/g in mice and human stool samples. Our novel sensor utilizes probe-modified S creen- P rinted E lectrodes (SPEs) capable of hybridizing target gene sequences associated with MDROs. The resulting probe/target complex generates a unique and highly sensitive signal detectable down to 10 atto molar or 10 CFU/mL of target TEM-1 gene. The use of these pre-functionalized SPEs reduces individual sample analysis time to less than an hour. Several target sequences from two chromosomal target genes (AmpC and AcrB found in E. coli ) have been identified and successfully detected in clinical stool samples with results comparable to the standard quantitative PCR method. Additional target genes associated with antibiotic resistance ( TEM-1, VanA, KPC and SHV ) have also been successfully detected in vitro and are ready for clinical evaluation. Future development includes multiplexing the sensor to simultaneously detect up to three MDROs target genes, including β-lactamases that hydrolyze β-lactams, the most commonly used antibiotics in clinical settings. This novel sensor platform will be a rapid, economical, point-of-care device with little requirement of reagent handling or technical training.
By monitoring opioid metabolites, wastewater-based epidemiology (WBE) could be an excellent tool for real-time information on consumption of illicit drugs. A key limitation of WBE is the reliance on costly laboratory-based techniques that require substantial infrastructure and trained personnel, resulting in long turnaround times. Here, we present an aptamer-based graphene field effect transistor (AptG-FET) platform for simultaneous detection of three different opioid metabolites. This platform provides a reliable, rapid, and inexpensive method for quantitative analysis of opioid metabolites in wastewater (WW). The platform delivers a limit of detection (LOD) 2-3 orders of magnitude lower than previous reports, but in line with the concentrations range (pg/ml to ng/ml) of these opioid metabolites present in real samples. To enable multianalyte detection we developed a facile, reproducible, and high yield fabrication process producing twenty G-FETs with integrated side gate platinum (Pt) electrodes on a single chip. Our devices achieved the simultaneous and selective multianalyte detection of three different metabolites: Noroxycodone (NX), 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and Norfentanyl (NF) in wastewater.
Human carbonic anhydrase 1 (CA1) has been suggested as a biomarker for identification of several diseases including cancers, pancreatitis, diabetes, and Sjogren’s syndrome. However, the lack of a rapid, cheap, accurate, and easy-to-use quantification technique has prevented widespread utilization of CA1 for practical clinical applications. To this end, we present a label-free electronic biosensor for detection of CA1 utilizing highly sensitive graphene field effect transistors (G-FETs) as a transducer and specific RNA aptamers as a probe. The binding of CA1 with aptamers resulted in a positive shift in Dirac voltage VD of the G-FETs, the magnitude of which depended on target concentration. These aptameric G-FET biosensors showed the binding affinity ( KD ) of ∼ 2.3 ng/ml (70 pM), which is four orders lower than that reported using a gel shift assay. This lower value of KD enabled us to achieve a detection range (10 pg/ml - 100 ng/ml) which is well in line with the clinically relevant range. These highly sensitive devices allowed us to further prove their clinical relevance by successfully detecting the presence of CA1 in human saliva samples. Utilization of this label-free biosensor could facilitate the early stage identification of various diseases associated with changes in concentration of CAs.